Our Values
Innovation, Collaboration, and Hope
Outsmarting cancer, together
Omico is a nationwide network of research and treatment centres that facilitates, supports and promotes clinical trials in genomic cancer medicine. Central to this is the use of molecular screening for the prevention and treatment of cancer.
Our Mission
Recent News
2020 Masterclass Publications and webinar recordings
View the "Demystifying the Molecular Tumour Board" Masterclass publication and webinar recordings
ASPiRATION study - first patient enrolled
The first patient has been enrolled into the ‘ASPiRATION’ Study. The study is looking at the impact and value of comprehensive genomic profiling (CGP), precision medicine and personalised healthcare (PHC) in newly diagnosed metastatic, non-squamous, non-small cell lung cancer patients.
Making a difference
3000 patients enrolled onto the Molecular Screening and Therapeutics (MoST) program, 1000 people have enrolled in the Genetic Cancer Risk in the Young (RisC) study and 95 people have joined the Surveillance study in Multi-Organ Cancer prone syndromes (SMOC+) - great news for cancer research.